February 22, 2007
ImmunoGen, Inc. Announces Webcast of Presentation at the Susquehanna Financial Group's SIGnificant Investment Options in Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 22, 2007--ImmunoGen, Inc. (Nasdaq: IMGN) today announced that its presentation at the Susquehanna Financial Group's first annual SIGnificant Investment Options in Healthcare Conference will be webcast live. The presentation is scheduled to begin at 4:30 p.m. ET on March 1, 2007, and will be given at the Omni Berkshire Place hotel in New York City. The presentation will provide an update on ImmunoGen.

The webcast can be accessed through the "Investor Relations" section of the ImmunoGen website, Following the live webcast, a replay of the presentation will be available at the same location until March 8, 2007.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer biopharmaceuticals. The Company's proprietary Tumor-Activated Prodrug (TAP) technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells. Two TAP compounds wholly owned by ImmunoGen are in clinical testing - huN901-DM1 and huC242-DM4. Companies licensing the right to develop anticancer compounds to specific targets using ImmunoGen's TAP technology include Biogen Idec, Biotest AG, Centocor (Johnson & Johnson), Genentech, and sanofi-aventis. Three anticancer compounds are in clinical testing through ImmunoGen's collaborations with other companies - AVE9633 and AVE1642, in development by sanofi-aventis, and trastuzumab-MCC-DM1, in development by Genentech.

ImmunoGen, Inc.
Carol Hausner
Executive Director, Investor Relations and Corporate Communications

ImmunoGen, Inc.



The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?